Last updated: 02/27/2026 16:00:11
Study to Evaluate the Safety and clinical efficacy of Augmentin® Extra Strength-600 in Children with Acute Otitis Media in India
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Multicenter, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 in Children with Acute Otitis Media (AOM) in India
Trial description: Augmentin (ES)-600 is a high-dose amoxicillin/clavulanic acid 14:1 formulation that allows administration at 90/6.4 milligrams (mg)/kilograms (kg)/day in two divided doses. Most physicians in India use the standard Augmentin (amoxicillin:clavulanic acid 7:1) (45/6.4 mg/kg/day) formulation and double the dose to achieve higher dose of amoxicillin/clavulanic acid at 90 mg/kg/day in pediatric acute otitis media (AOM) due to non-availability of Augmentin (ES)-600. Using the 7:1 formulation causes unnecessary exposure to higher proportionate dose of clavulanic acid (12.8 mg/kg/day) as a unit dose of 6.4 mg/kg/day of clavulanic acid is only required for efficacy against beta-lactamase producing AOM pathogens. Hence, there is an unmet need for availability of Augmentin (ES)-600 in India. This is an open label, single arm, multicenter, non-comparative study in participants aged 6 months to 12 years with AOM. It aims to assess the safety and clinical efficacy of Augmentin (ES)-600 administered in two divided doses, every 12 hours in pediatric population in India. AUGMENTIN is a registered trademark of the GlaxoSmithKline group of companies.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Number of participants with treatment emergent adverse events (TEAE) and serious adverse events (SAEs)
Timeframe: From start of treatment (Day 1) to follow-up visit at Day 28
Secondary outcomes:
Number of participants achieving Primary Clinical Response
Timeframe: From start of treatment (Day 1) to end of therapy visit at Day 12-14
Number of participants achieving Secondary Clinical response
Timeframe: From end of treatment visit (Day 12-14) to follow up visit at Day 22-28
Number of participants with protocol defined diarrhea (PDD) (due to study medication)
Timeframe: From start of treatment (Day 1) to end of therapy visit at Day 12-14
Interventions:
Drug: Augmentin (ES)-600
Enrollment:
310
Observational study model:
Not applicable
Primary completion date:
2022-12-11
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Otitis Media, Infections, Respiratory Tract, Respiratory Tract Infections
Product
Not applicable
Collaborators
IQVIA
Study date(s)
May 2022 to November 2022
Type
Interventional
Phase
4
Participation criteria
Sex
Female & Male
Age
6 Months - 12 Years
Accepts healthy volunteers
No
- Participants aged: 6 months to 12 years; no gender restriction.
- Diagnosis of AOM on basis of otoscopic findings as defined below:
- Weight more than 40 kg.
- Spontaneous perforation of the tympanic membrane and drainage for longer than 24 hours.
Inclusion and exclusion criteria
Inclusion criteria:
- Participants aged: 6 months to 12 years; no gender restriction.
- Diagnosis of AOM on basis of otoscopic findings as defined below: a. Purulent otorrhea of less than 24 hours duration or b. Middle ear effusion
- Middle ear effusion is evidenced by at least two of the following: 1) Decreased or absent tympanic mobility measured by pneumatic otoscopy, 2) Yellow or white discoloration of the tympanic membrane, or 3) Opacification of the tympanic membrane plus At least one of the following indicators of acute inflammation: 1) Ear pain within 24 hours, including unaccustomed tugging or rubbing of ear, 2) Marked redness of the tympanic membrane, or 3) Distinct fullness or bulging of the tympanic membrane.
- The participant and parent(s)/legal guardian(s) are willing and able to comply with the study protocol.
- In accordance with regional/local laws and regulations, the parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has given written assent, if applicable, to participate in the study.
Exclusion criteria:
- Weight more than 40 kg.
- Spontaneous perforation of the tympanic membrane and drainage for longer than 24 hours.
- Tympanoplastic tube(s) in place, or has anatomic abnormalities associated with recurrent AOM, prolonged middle ear effusion, including cleft palate or repair, high-arched palate or Down’s syndrome.
- A serious underlying disease as per clinician’s judgment.
- Concomitant infection which would preclude evaluation of the response of his/her acute otitis media to the study intervention.
- Pre-existing renal insufficiency (plasma creatinine greater than [>]1.5 times upper limit of normal range for age).
- Pre-existing liver disease(s) and/or hepatic dysfunction.
- Evidence of leukopenia and/or thrombocytopenia.
- History of previous hypersensitivity reaction to penicillins, cephalosporins or other beta-lactam antibiotics.
- History of Augmentin-associated cholestatic jaundice/hepatic dysfunction.
- History of phenylketonuria or a known hypersensitivity to aspartame.
- Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter bowel function.
- Currently receiving or has received more than one dose of systemic antibiotic therapy within one week prior to the initiation of the study. AOM treatment failures with Amoxicillin, erythromycin, sulfamethoxazole or Trimethoprim-Sulfamethoxazole are not subject to this criterion.
- Receipt of an investigational compound (non-Food and Drug Administration [FDA] and non- Drugs Controller General Of India [DCGI] approved) or device within the previous 30 days or five half-lives, whichever is longer, preceding the first dose of study intervention or during the study.
- Participants with symptoms suggestive of active Coronavirus Disease 2019 (COVID-19) infection (fever, cough, etc).
- Participants with known COVID-19 positive contacts within the past 14 days.
Trial location(s)
Location
GSK Investigational Site
Varanasi, Uttar Pradesh, India, 221001
Status
Study Complete
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2022-12-11
Actual study completion date
2022-12-11
Plain language summaries
Summary of results in plain language
Available language(s): English, Bengali, Hindi, Kannada, Marathi, Punjabi, Tamil (India), Telugu
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website